BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 27301426)

  • 21. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
    Hayes TK; Neel NF; Hu C; Gautam P; Chenard M; Long B; Aziz M; Kassner M; Bryant KL; Pierobon M; Marayati R; Kher S; George SD; Xu M; Wang-Gillam A; Samatar AA; Maitra A; Wennerberg K; Petricoin EF; Yin HH; Nelkin B; Cox AD; Yeh JJ; Der CJ
    Cancer Cell; 2016 Jan; 29(1):75-89. PubMed ID: 26725216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methionine Mistranslation Bypasses the Restraint of the Genetic Code to Generate Mutant Proteins with Distinct Activities.
    Wang X; Pan T
    PLoS Genet; 2015 Dec; 11(12):e1005745. PubMed ID: 26709516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer Cell Invasion in Three-dimensional Collagen Is Regulated Differentially by Gα13 Protein and Discoidin Domain Receptor 1-Par3 Protein Signaling.
    Chow CR; Ebine K; Knab LM; Bentrem DJ; Kumar K; Munshi HG
    J Biol Chem; 2016 Jan; 291(4):1605-1618. PubMed ID: 26589794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
    Caunt CJ; Sale MJ; Smith PD; Cook SJ
    Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
    Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
    Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
    Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
    Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
    Ferro R; Falasca M
    World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
    Infante JR; Somer BG; Park JO; Li CP; Scheulen ME; Kasubhai SM; Oh DY; Liu Y; Redhu S; Steplewski K; Le N
    Eur J Cancer; 2014 Aug; 50(12):2072-81. PubMed ID: 24915778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diversity of human tRNA genes from the 1000-genomes project.
    Parisien M; Wang X; Pan T
    RNA Biol; 2013 Dec; 10(12):1853-67. PubMed ID: 24448271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
    Villanueva J; Infante JR; Krepler C; Reyes-Uribe P; Samanta M; Chen HY; Li B; Swoboda RK; Wilson M; Vultur A; Fukunaba-Kalabis M; Wubbenhorst B; Chen TY; Liu Q; Sproesser K; DeMarini DJ; Gilmer TM; Martin AM; Marmorstein R; Schultz DC; Speicher DW; Karakousis GC; Xu W; Amaravadi RK; Xu X; Schuchter LM; Herlyn M; Nathanson KL
    Cell Rep; 2013 Sep; 4(6):1090-9. PubMed ID: 24055054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovering RNA-protein interactome by using chemical context profiling of the RNA-protein interface.
    Parisien M; Wang X; Perdrizet G; Lamphear C; Fierke CA; Maheshwari KC; Wilde MJ; Sosnick TR; Pan T
    Cell Rep; 2013 May; 3(5):1703-13. PubMed ID: 23665222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells.
    Pavon-Eternod M; Gomes S; Rosner MR; Pan T
    RNA; 2013 Apr; 19(4):461-6. PubMed ID: 23431330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. tRNA binding, structure, and localization of the human interferon-induced protein IFIT5.
    Katibah GE; Lee HJ; Huizar JP; Vogan JM; Alber T; Collins K
    Mol Cell; 2013 Feb; 49(4):743-50. PubMed ID: 23317505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11.
    Li M; Kao E; Gao X; Sandig H; Limmer K; Pavon-Eternod M; Jones TE; Landry S; Pan T; Weitzman MD; David M
    Nature; 2012 Nov; 491(7422):125-8. PubMed ID: 23000900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP; Marais R
    Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEK genomics in development and disease.
    Bromberg-White JL; Andersen NJ; Duesbery NS
    Brief Funct Genomics; 2012 Jul; 11(4):300-10. PubMed ID: 22753777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
    Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
    Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
    Nikolaev SI; Rimoldi D; Iseli C; Valsesia A; Robyr D; Gehrig C; Harshman K; Guipponi M; Bukach O; Zoete V; Michielin O; Muehlethaler K; Speiser D; Beckmann JS; Xenarios I; Halazonetis TD; Jongeneel CV; Stevenson BJ; Antonarakis SE
    Nat Genet; 2011 Dec; 44(2):133-9. PubMed ID: 22197931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mapping in vivo protein-RNA interactions at single-nucleotide resolution from HITS-CLIP data.
    Zhang C; Darnell RB
    Nat Biotechnol; 2011 Jun; 29(7):607-14. PubMed ID: 21633356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.